Both first generation antipsychotics (FGA’s) and second generation antipsychotics (SGA’s) are associated with a wide range of side effects that can lead to patient distress and noncompliance with treatment. First generation antipsychotics are strong D2 antagonists resulting in pronounced extra-pyramidal side effects and increased rates of hyperprolactinemia making them second-line treatments for schizophrenia (Werner). The SGA’s (risperidone, olanzapine, clozapine, quetiapine, paliperidone, aripirazole, and ziprasidone) are D2/5-HT2A antagonists and exhibit fewer extra-pyramidal manifestations and have therefore become first-line treatments in patients with newly-diagnosed schizophrenia (Werner). However, not all SGA’s are created equal and
…show more content…
Patients can benefit from approachable clinicians that establish rapport with patients by discussing patient beliefs, fears, motivation for treatment, and that encourage routine follow-up (Garcia). Additionally, patients have increased adherence with continuity of care by a single healthcare team, longer and more frequent visits with providers, and better physical access to the healthcare center of their choice (Garcia). (Mahone) In literature by Mahone et al, it is encouraged that providers engage in shared decision-making that places emphasis on the patient’s perspective when making treatment choices. In the same paper, it is encouraged to perform frequent reassessments of treatment goals as preferences and the patient’s ability to engage can change throughout course of treatment. Additionally, decreased insight into their illness is a risk factor to non-adherence that can be overcome with a strong patient-provider relationship and frequent psychotherapy (Mahone). This kind of treatment approach can give the patient a more positive perception of their mental illness and empower them by including them as a proactive member in their own recovery as well as encouraging long-term medication …show more content…
Between our limited knowledge of the etiology of psychiatric illnesses and patient free will, there are ample opportunities for ineffective treatment and patient relapse. Current research in the area is providing some solutions to the obstacles faced by patients and practitioners but there are limitations to the information we have based on current studies and there are still many unanswered
Patients can benefit from approachable clinicians that establish rapport with patients by discussing patient beliefs, fears, motivation for treatment, and that encourage routine follow-up (Garcia). Additionally, patients have increased adherence with continuity of care by a single healthcare team, longer and more frequent visits with providers, and better physical access to the healthcare center of their choice (Garcia). (Mahone) In literature by Mahone et al, it is encouraged that providers engage in shared decision-making that places emphasis on the patient’s perspective when making treatment choices. In the same paper, it is encouraged to perform frequent reassessments of treatment goals as preferences and the patient’s ability to engage can change throughout course of treatment. Additionally, decreased insight into their illness is a risk factor to non-adherence that can be overcome with a strong patient-provider relationship and frequent psychotherapy (Mahone). This kind of treatment approach can give the patient a more positive perception of their mental illness and empower them by including them as a proactive member in their own recovery as well as encouraging long-term medication …show more content…
Between our limited knowledge of the etiology of psychiatric illnesses and patient free will, there are ample opportunities for ineffective treatment and patient relapse. Current research in the area is providing some solutions to the obstacles faced by patients and practitioners but there are limitations to the information we have based on current studies and there are still many unanswered